Clinical Trials · NCT01257802
GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Joseph Mccune
- Enrollment
- 14
- Start date
- May 2011
- Locations
- 2 sites, United States
- Primary endpoint
- Anti-mullerian Hormone (AMH) Measured as a Continuous Variable, Specifically Assessing the Intra-person Change From Study Entry (Day 0) to 6-month Post-intervention Visit